What is 23andMe Holding Co.?
operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally.
MEHCQ · Verdict
Limited reward · elevated risk
MEHCQ stands out on balance sheet and valuation, but watch the volatility signal.
Based on 88% data coverage
MEHCQ · Verdict
Current ratio 0.83
Above average
Weak vs peers
Rev -11.3% CAGR · earnings +8.9%
-93% free-cash-flow margin
-148% net margin · -406% ROE
Model-based scoring. For information only — not financial advice.
operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 96.40M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.